Monocyte heterogeneity in human cardiovascular disease

Area of Science:

• Immunology
• Cardiovascular Research
• Cell Biology

Background:

• Atherosclerosis is an inflammatory disease involving monocytes and macrophages.
• Monocyte heterogeneity, specifically classical, intermediate, and nonclassical subsets, is increasingly recognized.
• Previous studies often overlooked monocyte subset differences, impacting cardiovascular event prediction.

Purpose of the Study:

• To investigate the role of distinct human monocyte subsets in atherosclerosis.
• To highlight the importance of monocyte heterogeneity in cardiovascular disease research.
• To explore potential therapeutic targets within specific monocyte subsets.

Main Methods:

• Distinguishing human monocyte subsets (classical, intermediate, nonclassical) using specific cell surface markers (CD14, CD16).
• Utilizing appropriate staining and gating strategies for accurate monocyte subset enumeration.
• Reviewing experimental studies in murine models and pilot clinical data on human atherosclerosis.

Main Results:

• Experimental studies in mice established subset-specific contributions to atherogenesis.
• Interspecies differences limit direct extrapolation from murine to human pathology.
• Pilot clinical studies suggest intermediate CD14(++)CD16(+) monocytes are prominently involved in human atherosclerosis.

Conclusions:

• Monocyte heterogeneity is critical for understanding atherosclerosis.
• Intermediate monocytes (CD14++CD16+) show significant involvement in human atherosclerosis.
• Targeting intermediate monocytes could offer a future therapeutic strategy for atherosclerosis.